Norwich Pharmaceuticals introduces Clinical Services Division

NORWICH – Norwich Pharmaceuticals, Inc. (Norwich), a leader in full-service contract development and manufacturing, today announced the formation of Norwich Clinical Services to provide clinical testing capabilities that will further expand the company’s third party services. Norwich Clinical Services will offer a complete range of clinical research capabilities including Phase I – IV trials, bioanalytical studies and pharmacovigilance monitoring services.  



“The introduction of Norwich Clinical Services underscores our strategic focus to provide customers with a comprehensive solution for all stages of product life cycle management,” said Doug Drysdale, chief executive officer of Alvogen, a company that includes Norwich Pharmaceuticals and Norwich Clinical Services. “We have assembled the highest level of professional expertise to ensure Norwich Clinical Services matches our tradition of unparalleled quality standards and delivers contract pharmaceutical services with everyday excellence.”


There's more to this story! You're only seeing 26% of the story. Subscribe now to get immediate access to the rest of the story as well as our whole online offering.

Today's Other Stories



© 2014 Snyder Communications/The Evening Sun
29 Lackawanna Avenue, Norwich, NY 13815 - (607) 334-3276
We're on Facebook